About this item:

156 Views | 180 Downloads

Author Notes:

Correspondence should be addressed to Daniel E. Abbott; abbott@surgery.wisc.edu.

Drs. Abbott and Schwartz were involved in the manuscript generation, editing, and interpretation of all data.

Drs. Vande Walle and Krasnick were involved in the generation and interpretation of all data.

Drs. Winslow, Ethun, Tran, Poultsides, Tseng, Roggin, Grignol, Howard, Fields, Mogal, Clarke, Senehi, Votanopoulos, and Cardona were involved in the generation and editing of the manuscript.

We would like to thank Dr. Jesse Davidson, MD, from Washington University who assisted in the preliminary data gathering and abstract generation.

The authors declare that they have no conflicts of interest.


Research Funding:

This research was not funded by any specific grant, but was supported by Daniel Abbott, MD, as a part of his employment.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Surgery

Predictors of Disease-Free and Overall Survival in Retroperitoneal Sarcomas: A modern 16 year Multi-Institutional Study from the United States Sarcoma Collaboration (USSC)

Show all authors Show less authors


Journal Title:



Volume 25


, Pages S195-S195

Type of Work:

Article | Final Publisher PDF


Background. Retroperitoneal sarcomas (RPS) comprise approximately 15% of all soft-tissue sarcomas and frequently associated with significant morbidity and as little as 30% 5-year survival. Here, we provide a large, contemporary, and multi-institutional experience to determine which tumor, patient, and treatment characteristics are associated with long-term outcomes in RPS. Methods. 571 patients with primary RPS were identified from the United States Sarcoma Collaboration (USSC). RPS patients who underwent resection from January 2000 to April 2016 were included with patient, tumor, and treatment-specific variables investigated as independent predictors of survival. Survival analyses for disease-free and overall survival were conducted using Kaplan-Meier and Cox proportional hazards model methods. Results. The study cohort was 55% female, with a median age of 58.9 years (IQR: 48.6-70.0). The most common tumor histiotypes were liposarcoma (34%) and leiomyosarcoma (28%). Median follow-up was 30.6 months (IQR: 11.2-60.4). Median disease-free survival was 35.3 months (95% CI: 27.6-43.0), with multivariate predictors of poorer disease-free survival including higher grade tumors, nodal-positive disease, and multivisceral resection. Median overall survival was 81.6 months (95% CI: 66.3-96.8). Multivariate predictors of shorter overall survival included higher grade tumors, nodal-positive and multifocal disease, systemic chemotherapy, and grossly positive margins (R2) following resection. Conclusions. The strongest predictors of disease-free and overall survival are tumor-specific characteristics, while surgical factors are less impactful. Nonsurgical therapies are not associated with improved outcomes despite persistent interest and utilization. Complete macroscopic resection (R0/R1) remains a persistent potentially modifiable risk factor associated with improved overall survival in patients with retroperitoneal sarcomas.

Copyright information:

© 2019 Patrick B. Schwartz et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote